Gilead, not sweating looming tariff threats, stands by long-acting PrEP launch
As potential HIV policy changes, looming tariffs and sweeping cuts across federal drug and health agencies are posing a concern for investors, Gilead is engaging with policymakers to stress the importance of lenacapivir for PrEP, CEO Daniel O'Day said.
